51135-96-7

Basic information

• Product Name: 4-BENZYL-4-HYDROXYPIPERIDINE
• Synonyms: 4-benzylpiperidin-4-ol;4-Benzyl-4-hydroxypiperidine,95%;4-Benzyl-4-hydroxypiperidine, 95% 1GR;4-benzyl-4-piperidino;4-Piperidinol, 4-(phenylmethyl)-;4-Piperidinol, 4-benzyl-;Piperidin-4-ol, 4-benzyl-;Piperidin-4-ol, 4-phenylmethyl-
• CAS NO: 51135-96-7
• Molecular Formula: C₁₂H₁₇NO
• Molecular Weight: 191.27
• EINECS: 257-003-7
• Mol File: 51135-96-7.mol

Chemical Properties

• Melting Point: 80-85 °C
• Boiling Point: 327.03°C (rough estimate)
• Flash Point: 128.4 °C
• Appearance: Yellow to brownish/Crystalline Powder
• Density: 1.0096 (rough estimate)
• Vapor Pressure: 7.37E-05mmHg at 25°C
• Refractive Index: 1.5212 (estimate)
• Storage Temp.: 2-8°C
• PKA: 14.94±0.20(Predicted)
• Water Solubility: Slightly soluble in water.
• Sensitive: Hygroscopic
• BRN: 1451803
• CAS DataBase Reference: 4-BENZYL-4-HYDROXYPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYL-4-HYDROXYPIPERIDINE(51135-96-7)
• EPA Substance Registry System: 4-BENZYL-4-HYDROXYPIPERIDINE(51135-96-7)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-22
• Safety Statements: 37/39-26
• RTECS: TN6836000
• Hazardous Substances Data: 51135-96-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Benzyl-4-hydroxypiperidine is used as a synthetic building block for the development of various compounds with therapeutic applications. Its versatile structure allows for the creation of a wide range of pharmaceuticals, including those with potential use in the treatment of various medical conditions.
Used in Synthesis of Histamine H3 Antagonists:
4-Benzyl-4-hydroxypiperidine is used as a key intermediate in the synthesis of 4-Benzimidazolyl-piperidinylcarbonyl-piperidine analogs, which are known as histamine H3 antagonists. These compounds have potential applications in the treatment of various conditions, such as cognitive disorders, sleep-wake regulation, and other central nervous system-related issues. The development of histamine H3 antagonists using 4-Benzyl-4-hydroxypiperidine as a building block can lead to the discovery of novel therapeutic agents with improved efficacy and safety profiles.

InChI:InChI=1/C12H17NO/c14-12(6-8-13-9-7-12)10-11-4-2-1-3-5-11/h1-5,13-14H,6-10H2/p+1

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 6921-34-2 benzylmagnesium chloride 
• 191327-87-4 tert-butyl 4-benzyl-4-hydroxypiperidine-1-carboxylate 
• 100-39-0 benzyl bromide 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 1589-82-8 phenylmagnesium bromide 

Downstream Products

• 138047-40-2 3-(4-Benzyl-4-hydroxypiperidino)-7-(triiso-propylsilyloxy)chromen-4-one 
• 191327-87-4 tert-butyl 4-benzyl-4-hydroxypiperidine-1-carboxylate 
• 191327-89-6 4-benzyl-4-fluoropiperidine 
• 191327-88-5 1-tert-butyloxycarbonyl-4-benzyl-4-fluoropiperidine 
• 34597-98-3 1-[β-(2-methyl-3-indolyl)propionyl]-4-benzyl-4-hydroxypiperidine 
• 1623011-33-5 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(thieno[3,2-b]pyridin-7-yl)urea 
• 1623011-16-4 1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(2-methylthieno-[3,2-b]pyridin-7-yl)urea 
• 1623011-18-6 1-(2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl)-3-(3-bromothieno-[3,2-b]pyridin-7-yl)urea 
• 1623011-20-0 1-[2-(4-benzyl-4-hydroxypiperidin-1-yl)ethyl]-3-(5-methylthieno-[3,2-b]pyridin-7-yl)urea 

Relevant articles and documents

COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASES

The present invention refers to relates to compound for treating inflammatory diseases, said formula I compounds represented, such as, a pharmaceutically acceptable salts, or their, or a hydrate thereof is characterized in that the, polymerized. According to the present invention, interacting with-path 5-LOX a compound or interference, in particular 5- oh height[...]width it recovers sourly, in sacrifice, which display inhibitory effects can be provides compounds having. (by machine translation)

Synthesis and SAR of thieno[3,2-b]pyridinyl urea derivatives as urotensin-II receptor antagonists

The preparation and SAR profile of thieno[3,2-b]pyridinyl urea derivatives as novel and potent urotensin-II receptor antagonists are described. An activity optimization study, probing the effects of substituents on thieno[3,2-b]pyridinyl core and benzyl group of the piperidinyl moiety, led to the identification of p-fluorobenzyl substituted thieno[3,2-b]pyridinyl urea 6n as a highly potent UT antagonist with an IC50 value of 13 nM. Although 6n displays good metabolic stability and low hERG binding activity, it has an unacceptable oral bioavailability.

ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS

The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors, hi particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase 1 (SCD 1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase (SCD) inhibitors.

Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin- 1-yl)propyl)indoles gives selective human 5-HT(1D) receptor ligands with improved pharmacokinetic profiles

It has previously been reported that a 3-(3-(piperazin-1- yl)propyl)indole series of 5-HT(1D) receptor ligands have pharmacokinetic advantages over the corresponding 3-(3-(piperidin-1-yl)propyl)indole series and that the reduced pK(a) of the piperazines compared to the piperidines may be one possible explanation for these differences. To investigate this proposal we have developed versatile synthetic strategies for the incorporation of fluorine into these ligands, producing novel series of 4- fluoropiperidines, 3-fluoro-4-aminopiperidines, and both piperazine and piperidine derivatives with one or two fluorines in the propyl linker. Ligands were identified which maintained high affinity and selectivity for the 5-HT(1D) receptor and showed agonist efficacy in vitro. The incorporation of fluorine was found to significantly reduce the pK(a) of the compounds, and this reduction of basicity was shown to have a dramatic, beneficial influence on oral absorption, although the effect on oral bioavailability could not always be accurately predicted.

Inhibitors of farnesyl-protein transferase

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and treatment of cancer.

Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans

2-Piperidinoalkyl-1,4-benzodioxans, e.g. those of the formula STR1 and acid addition salts thereof are neuroleptic agents.

2-Piperidinoalkyl-1,4-benzodioxans

2-Piperidinoalkyl-1,4-benzodioxans, e.g. those of the formula STR1 AND ACID ADDITION SALTS THEREOF ARE NEUROLEPTIC AGENTS.

2-Piperidinoalkyl-1,4-benzodioxans

2-Piperidinoalkyl-1,4 benzodioxans, e.g. those of the formula STR1 AND ACID ADDITION SALTS THEREOF ARE NEUROLEPTIC AGENTS.